[开放获取]    白癜风靶向药物临床应用进展及前景

doi:10.35541/cjd.20230509

Abstract

Abstract: 【Abstract】 In recent years, great progress has been made in the research on the pathogenesis of vitiligo, and many new treatment methods and drugs have emerged. Interferon-γ-activated Janus kinase （JAK） signaling and melanocyte regeneration signaling pathways are the most concerned targets in the research on the treatment of vitiligo. This article summarizes the efficacy of current new drugs targeting these pathways and the experience in applying these drugs in the treatment of vitiligo. JAK inhibitors are currently the most promising new drugs for the treatment of vitiligo, and their efficacy can be improved in combination with phototherapy.

Key words: Vitiligo, Janus kinases, Enzyme inhibitors, Tofacitinib, Simvastatin, Alpha-melanocyte stimulating hormone

Li Shuli, Li Chunying. Clinical application of targeted drugs in vitiligo: progress and prospects[J]. Chinese Journal of Dermatology, 2024, 57(1): 12-16.doi:10.35541/cjd.20230509

References ［27］

［1］	Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis⁃directed therapy［J］. JAMA Dermatol, 2015,151（10）:1110⁃1112. doi: 10.1001/jamadermatol.2015.1520.
［2］	Liu LY, Strassner JP, Refat MA, et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure［J］. J Am Acad Dermatol, 2017,77（4）:675⁃682.e1. doi: 10.1016/j.jaad.2017.05.043.
［3］	Kim SR, Heaton H, Liu LY, et al. Rapid repigmentation of vitiligo using tofacitinib plus low⁃dose, narrowband UV⁃B phototherapy［J］. JAMA Dermatol, 2018,154（3）:370⁃371. doi: 10.1001/jamadermatol.2017.5778.
［4］	Fang WC, Chiu SH, Lin SY, et al. Evaluation of low⁃dose tofacitinib combining narrowband UVB therapy for treating vitiligo patients who had failed previous therapy: a pilot study［J］. Photodermatol Photoimmunol Photomed, 2021,37（4）:345⁃347. doi: 10.1111/phpp.12661.
［5］	Gianfaldoni S, Tchernev G, Wollina U, et al. Micro ⁃ focused phototherapy associated to Janus kinase inhibitor: a promising valid therapeutic option for patients with localized vitiligo［J］. Open Access Maced J Med Sci, 2018,6（1）:46⁃48. doi: 10.3889/oamjms.2018.042.
［6］	Fang WC, Lin SY, Huang SM, et al. Low⁃dose tofacitinib with 308⁃nm excimer therapy successfully induced repigmentation in patients with refractory vitiligo［J］. Clin Exp Dermatol, 2022,47（4）:782⁃783. doi: 10.1111/ced.15070.
［7］	Song H, Hu Z, Zhang S, et al. Effectiveness and safety of tofacitinib combined with narrowband ultraviolet B phototherapy for patients with refractory vitiligo in real⁃world clinical practice［J］. Dermatol Ther, 2022,35（11）:e15821. doi: 10.1111/dth. 15821.
［8］	Xu Z, Xing X, Xuan Y, et al. Progressive nonsegmental vitiligo successfully treated with oral tofacitinib and narrow⁃band UVB: a case report of 2⁃year follow⁃up［J］. Photodermatol Photoimmunol Photomed, 2023,39（6）:663⁃666. doi: 10.1111/phpp.12900.
［9］	Mobasher P, Guerra R, Li SJ, et al. Open⁃label pilot study of tofacitinib 2% for the treatment of refractory vitiligo［J］. Br J Dermatol, 2020,182（4）:1047⁃1049. doi: 10.1111/bjd.18606.
［10］	McKesey J, Pandya AG. A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo［J］. J Am Acad Dermatol, 2019,81（2）:646⁃648. doi: 10.1016/j.jaad.2019.04.032.
［11］	Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata （AA）［J］. J Am Acad Dermatol, 2016,74（2）:370⁃371. doi: 10.1016/j.jaad.2015.09.073.
［12］	Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib［J］. J Am Acad Dermatol, 2017,76（6）:1054⁃1060.e1. doi: 10.1016/j.jaad. 2017.02.049.
［13］	Joshipura D, Alomran A, Zancanaro P, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32⁃week open⁃label extension study with optional narrow⁃band ultraviolet B［J］. J Am Acad Dermatol, 2018,78（6）:1205⁃1207.e1. doi: 10.1016/j.jaad.2018.02.023.
［14］	Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial［J］. Lancet, 2020,396（10244）:110⁃120. doi: 10.1016/S0140⁃6736（20）30609⁃7.
［15］	Rosmarin D, Passeron T, Pandya AG, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo［J］. N Engl J Med, 2022,387（16）:1445⁃1455. doi: 10.1056/NEJMoa 2118828.
［16］	Mumford BP, Gibson A, Chong AH. Repigmentation of vitiligo with oral baricitinib［J］. Australas J Dermatol, 2020,61（4）:374⁃376. doi: 10.1111/ajd.13348.
［17］	Li X, Sun Y, Du J, et al. Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB⁃UVB phototherapy［J］. Clin Cosmet Investig Dermatol, 2023,16:635⁃638. doi: 10.2147/CCID.S396430.
［18］	Pan T, Mu Y, Shi X, et al. Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report［J］. J Dermatolog Treat, 2023,34（1）:2200873. doi: 10.1080/09546634.2023.2200873.
［19］	Su X, Luo R, Ruan S, et al. Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo［J］. J Am Acad Dermatol, 2023:S0190⁃9622（23）02410⁃02416. doi: 10.1016/j.jaad.2023.07.1016.
［20］	Ezzedine K, Peeva E, Yamaguchi Y, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial［J］. J Am Acad Dermatol, 2023,88（2）:395⁃403. doi: 10.1016/j.jaad.2022.11.005.
［21］	Noël M, Gagné C, Bergeron J, et al. Positive pleiotropic effects of HMG⁃CoA reductase inhibitor on vitiligo［J］. Lipids Health Dis, 2004,3:7. doi: 10.1186/1476⁃511X⁃3⁃7.
［22］	Vanderweil SG, Amano S, Ko WC, et al. A double⁃blind, placebo⁃controlled, phase⁃Ⅱ clinical trial to evaluate oral simvastatin as a treatment for vitiligo［J］. J Am Acad Dermatol, 2017,76（1）:150⁃151.e3. doi: 10.1016/j.jaad.2016.06.015.
［23］	Nguyen S, Chuah SY, Fontas E, et al. Atorvastatin in combination with narrowband UV⁃B in adult patients with active vitiligo: a randomized clinical trial［J］. JAMA Dermatol, 2018,154（6）:725⁃726. doi: 10.1001/jamadermatol.2017.6401.
［24］	Niezgoda A, Winnicki A, Kosmalski T, et al. The evaluation of vitiligous lesions repigmentation after the administration of atorvastatin calcium salt and simvastatin⁃acid sodium salt in patients with active vitiligo （EVRAAS）, a pilot study: study protocol for a randomized controlled trial［J］. Trials, 2019,20（1）:78. doi: 10.1186/s13063⁃018⁃3168⁃4.
［25］	Grimes PE, Hamzavi I, Lebwohl M, et al. The efficacy of afamelanotide and narrowband UV⁃B phototherapy for repigmen⁃tation of vitiligo［J］. JAMA Dermatol, 2013,149（1）:68⁃73. doi: 10.1001/2013.jamadermatol.386.
［26］	Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and narrowband UV⁃B phototherapy for the treatment of vitiligo: a randomized multicenter trial［J］. JAMA Dermatol, 2015,151（1）:42⁃50. doi: 10.1001/jamadermatol.2014.1875.
［27］	Toh J, Chuah SY, Jhingan A, et al. Afamelanotide implants and narrow⁃band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians［J］. J Am Acad Dermatol, 2020,82（6）:1517⁃1519. doi: 10.1016/j.jaad.2020.01.035.

[1]	Dermatology Professional Committee of Chinese Research Hospital Society, China Dermatologist Association. Guideline on phototherapy for vitiligo （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(3): 197-208.
[2]	Li Ming, Li Yan, Li Linfeng. JAK inhibitors for the treatment of moderate-to-severe atopic dermatitis [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220342-e0220342.
[3]	Li Qianwen, Liao Zhikai, Le Yue, Duan Bolin, Geng Mengmeng, Lei Tiechi. The antioxidant Tempol inhibits pigment loss in tail skin of a mouse model of immune-induced vitiligo under oxidative stress [J]. Chinese Journal of Dermatology, 2025, 58(2): 126-131.
[4]	Song Pu, Liu Yu, Guo Sen, Li Shuli, Liu Ling, Li Chunying. Mast cell-derived chemokine C-C motif ligand 5 affects the migration of CD8⁺ T cells in vitiligo under oxidative stress [J]. Chinese Journal of Dermatology, 2025, 0(2): 20230513-e20230513.
[5]	Zhou Miaoni, Sheng Anqi, Fu Lifang, Jin Rong, Xu Wen, Wei Xiaodong, Xu Ai′e . Efficacy and safety of tea polyphenol antioxidant gel combined with narrow-band ultraviolet B in the treatment of vitiligo: a single-center randomized controlled trial [J]. Chinese Journal of Dermatology, 2025, 0(2): 20240421-e20240421.
[6]	Luo Li, Zhang Bona, Wu Wei, Tang Wenjing, Li Yuehua, Liu Xiaoli, Ma Yanan, Li Cuicui, Qi Mengyan, Sun Ni, Shi Qiong. Efficacy and safety of 308-nm excimer laser and 308-nm excimer lamp in the treatment of 194 children with vitiligo: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(8): 721-727.
[7]	Chen Jiaxi, Yi Xiuli, Li Chunying, Li Shuli. Study on the protective effect of folic acid against oxidative stress-induced damage to melanocytes in vitro [J]. Chinese Journal of Dermatology, 2024, 57(6): 547-552.
[8]	Zhang Dimin, Cao Cheng, Zhou Miaoni, Sheng Anqi, Lin Fuquan, Xu Ai′e. Analysis of disease control rate and its influencing factors in patients with progressive non-segmental vitiligo after combined treatment with compound betamethasone injection [J]. Chinese Journal of Dermatology, 2024, 57(4): 350-354.
[9]	Yuan Liyan, Yu Xiaoling, Wang Xiaohua, Yang Bin. TYK2 inhibitors for plaque psoriasis: mechanism of action and advances in clinical research [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220740-e0220740.
[10]	Zhang Yude, Wang Hongjuan, Kang Xiaojing. Stem cell therapy for vitiligo: advances in basic and clinical research [J]. Chinese Journal of Dermatology, 2024, 0(3): 20240127-e20240127.
[11]	Liu Lyuye, Zhang Junling. Ferroptosis in common skin diseases [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220783-e20220783.
[12]	Dai Yeqin, Song Xiuzu. Application of hair follicle transplantation and follicular cell suspension transplantation in the treatment of vitiligo [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230274-e0230274.
[13]	Sun Weiwei, Chen Jianru, Li Shuli, Gao Tianwen, Li Chunying . Analysis of depression-like behavioral performances of mouse models of vitiligo [J]. Chinese Journal of Dermatology, 2024, 57(2): 147-154.
[14]	Pigmentary Disorder Group, Combination of Traditional and Western Medicine Dermatology, Research Center for Vitiligo, Chinese Society of Dermatology, Committee on Pigmentation Disorders, China Dermatologist Association . Consensus on the diagnosis and treatment of vitiligo （2024 version） [J]. Chinese Journal of Dermatology, 2024, 57(12): 1065-1070.
[15]	Yang Siyan, Ma Lin, Zhang Bin. Application of crisaborole ointment in dermatology [J]. Chinese Journal of Dermatology, 2024, 57(10): 962-966.

Clinical application of targeted drugs in vitiligo: progress and prospects

PDF

Knowledge

Abstract

Cite this article

share this article

References ［27］

Related Articles 15

Metrics

Comments

Recommended 10